SPOTLIGHT -
There are a few things that we all agree on, as reflected in a recent consensus statement.
Why Clinicians Should Be Excited About Austedo XR
Not All That Writhes Is Tardive Dyskinesia
Managing Tardive Dyskinesia: New Data from Phase 3 Study of Ingrezza
The 2024 APA Annual Meeting: Monday, May 6
Neurocrine Biosciences Announces Collaboration With Participants of Tardive Dyskinesia Awareness Week
Tardive Dyskinesia in US Antipsychotic Users